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1. Summary
It is important to note that all guidelines relating to how services respond to the
COVID-19 are evolving and subject to change so it is important to check the major
information websites from time to time for updates and revisions.
COVID-19 Case Definition Change (18.05.20)
Dear Colleagues
General Case Definition for the Public
From today the general clinical case definition for COVID-19 has been updated to
include loss of or change in smell or taste. It is now:
New continuous cough OR fever OR loss of/ change in smell or taste
Everyone, including health and social care workers, should self-isolate if they
develop a new continuous cough or fever or loss of/ change in smell or taste. The
individual’s household should also self-isolate for 14 days as per the current
guidelines. The individual should stay at home for 7 days, or longer if they still have
a fever.
Thank you for your ongoing work in this pandemic.
Some of the following guidance was developed at pace by various professional
bodies as the COVID-19 infection began to spread through the UK during February
and March 2020. When COVID-19 reached Northern Ireland, Addiction Services
recognised the difficulties in safely assessing patients face-to-face while community
pharmacies were facing very high demand on their services and at the same time
needing to implement appropriate infection control measures.
Within Northern Ireland, HSCB directed a stand-down of community pharmacy
supervised consumption arrangements for opioid substitution treatment on the 18
March 2020. Around that same time, addiction services in Northern Ireland were also
making massive changes to their working practice, moving mainly to assessment
and reviews by telephone or videolinks. The three specialist inpatient addictions
units based in Holywell Hospital, Downshire Hospital and Tyrone and Fermanagh
Hospital were also closed to admissions, as indeed were the alcohol and drug
residential units based at Carlisle House Belfast and Northlands Centre Derry. All of
these units use group work as a major part of the treatment programme, making it
very difficult or impossible to observe social distancing and hence increasing the risk
of COVID-19 infection to both patients and staff.
It is recognised that the management of substance misuse services in NI is currently
in a period of increased risk in what is already a risky clinical scenario. Services here
are now working to a rebuilding plan to re-establish existing services and referrals,
and to begin treating patients who may have been on a waiting list for a specialist
intervention. Services are also preparing for a potential surge in new referrals. One
of the challenges facing all alcohol and drug services will be to ensure that premises
are safe for both patients and staff in terms of social distancing and comply with the
necessary infection control measures.
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People at risk of alcohol or drug related harm may be particularly vulnerable to
COVID-19 infection and may have a range of family, financial, mental or physical
health problems and housing issues which compound their problems. It is essential
that appropriate services are available to support them through the COVID-19
pandemic and beyond.
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2. Guidance for Commissioners and Providers of Services for people
who use drugs or alcohol in Northern Ireland
 It is vital that alcohol and drug and services keep operating, as far as possible, as
they provide essential support to protect vulnerable people who are at greater
risk from coronavirus (COVID-19) and help reduce the burden on other
healthcare services.
 However, it is acknowledged that alcohol and drug services face major
challenges in maintaining services during the COVID-19 pandemic for a variety of
reasons:-
 Some services/sites/clinics are designed in ways that make maintaining
social distancing and implementing appropriate infection control measures
difficult;
 difficulties in carrying out drug testing, breathalysers or other physical
healthcare checks;
 difficulties in ensuring opioid substitute treatments can be supervised or
regularly dispensed from a community pharmacy in keeping with best
practice; and
 staff shortages due to COVID-19 infection, those who are isolating at
home for 14 days after being in contact with someone with COVID-19
infection or those who are shielding for health reasons.
 Services should keep face-to-face contacts between staff and service users to a
minimum and minimise the use of biological drug testing and breathalysers,
where safe to do so.
 Follow up-to-date guidance for infection prevention and control, including hand-
washing, surface-cleaning, isolating people and sending staff home. Additional
guidance on these topics can be found on the Public Health Agency website
Everyone must help stop coronavirus spreading.
 Arrangements for prescribing and dispensing of medicines used in treatment may
need to be changed to take account of service and pharmacy closures, staff
unavailability, patients having to maintain social distance or self-isolate, including
the most vulnerable being shielded and the need to reduce the spread of COVID-
19.
 Measures to reduce alcohol and drug-related harm, such as Needle and Syringe
Exchange Scheme (NSES) programmes, take-home naloxone, thiamine, advice
on gradual reduction of alcohol consumption should all be increased where
possible.
 Drug and alcohol treatment staff are included in the government’s definition of




The most common symptoms of COVID-19 are a new, continuous cough or a high
temperature or loss of/ change in smell or taste. For most people, COVID-19 will be
a mild infection. It may be more severe for those who are vulnerable because of pre-
existing and underlying conditions.
The symptoms of COVID-19 may be confused with withdrawal symptoms. Anyone
showing symptoms that could be COVID-19 should be assumed to be infected and
managed appropriately. They should be referred to be tested for the virus and
treated according to the results.
It is important to note that the 4 UK CMOs have updated the COVID-19 general
case definition on 18 May 2020 as follows:-
COVID-19 Case Definition Change (18.05.20)
Dear Colleagues
General Case Definition for the Public
From today the general clinical case definition for COVID-19 has been updated to
include loss of or change in smell or taste. It is now:
New continuous cough OR fever OR loss of/ change in smell or taste
Everyone, including health and social care workers, should self-isolate if they
develop a new continuous cough or fever or loss of/ change in smell or taste.
The individual’s household should also self-isolate for 14 days as per the current
guidelines. The individual should stay at home for 7 days, or longer if they still have
a fever.
Thank you for your ongoing work in this pandemic
Signed by the 4 UK CMOs
Additional information on a range of topics relating to COVID-19 (coronavirus) can be
accessed on the Public Health Agency website or through the COVID-19 app which is
available through Google Play or Apple app stores (see below)
Public Health Agency website – COVID-19 (coronavirus)
 Everyone must help stop coronavirus spreading
 Preventing the spread of infection
 What should I do if I think I have COVID-19?
 Looking after yourself and your family
 Testing
 Travel
 Older people and people with an underlying health condition
 Diabetes
 People with a hearing impairment or who are deaf
 Looking after your wellbeing while staying at home
 Pregnancy
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 People with a learning disability
 Screening
 Bereavement
 Public information downloads
https://www.publichealth.hscni.net/covid-19-coronavirus
Download the StopCOVID NI contact tracing App
StopCOVID NI is a free health service app for your mobile phone. It will help us to
protect each other and slow the spread of coronavirus (COVID-19).
Using the Stop COVID NI app along with the existing public health measures will
help us all stay safe when we meet up, socialise, work or travel.
The app tells you automatically if you’ve been near someone who tests positive.
It also tells others if you test positive, but will never know or share your identity or
location.
It uses the Google and Apple interface to access Bluetooth and anonymously record
other nearby phones. If a user has a positive test for COVID-19 an alert is sent to all
other users. Their app then runs a probability check to determine whether there is
any risk to the user, and if relevant provides advice to self-isolate. You can find out
more about how the app works here.
Most people spreading the virus don’t know they have it. So the more people using
the app, the more lives we save.
As we go out more, let’s all keep doing our bit.
Download ‘StopCOVID NI’ from the Google or Apple App store now to help stop the
spread of coronavirus.
The app is available to anyone over the age of 18 in Northern Ireland.
7
4. Protection against Infection
Staff of residential and non-residential drug and alcohol services should wash their
hands frequently and should have access to hand sanitising gels. Depending on their
patient contact and activities, they may need to be supplied with personal protective
equipment (PPE) and trained in how to use it.
Face-to-face contact should be minimised. In advance of an appointment, staff
should contact the service user to check if they have had a new, continuous cough
or a high temperature or loss of/change in smell or taste in the previous 7 days. If
they have, they will need to remain in self-isolation for 7 days from when their
symptoms started. Those with whom they share a household will also need to self-
isolate, following the current guidance. Alternative arrangements then need to be
made as below.
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5. Considerations for People Using Drugs and/or Alcohol
Issues for consideration in relation to COVID-19 may be heightened for people who
are currently using alcohol or drugs or both. Some drug and alcohol service users
may be more at risk from COVID-19-related illness or complications. Typically, this
includes:
 women who are pregnant
 people who are 70 years or older
 people under 70 with underlying medical conditions, including asthma or other
chronic pulmonary conditions and cardiovascular disease
There is also emerging evidence that people from black and minority ethnic (BAME)
backgrounds are dying disproportionately from COVID-19 infection. Other groups at
increased risk appear to be males and people with hypertension, obesity or diabetes
mellitus.
COVID-19 will have specific implications for people experiencing homelessness and
rough sleeping, some of whom may also use alcohol or drugs. There is a significant
work programme underway across government to support areas to identify
appropriate accommodation and wraparound health services that will enable this
group to follow social distancing advice and self-isolate if needed. There is also
practical guidance for homeless providers in Northern Ireland. Some key contact
details from that publication are shown below:-
COVID-19: GUIDANCE FOR HOMELESS PROVIDERS IN NORTHERN IRELAND
Version 2 April 2020
The definition of an outbreak is 2 or more cases in a 24-hour period with similar
signs & symptoms, if this situation arises the hostel can contact the PHA via the
duty room contact number at 0300 555 0119. The PHA can provide advice &
infection prevention & control guidance to the hostel.
The Public Health Agency has provided a point of contact for hostel providers:
Deirdre Webb, Assistant Director of Public Health Nursing
(deirdre.webb@hscni.net, phone: 079 20186497). This should be used to request
detailed advice on medical issues and infection control in hostels.
The Department for Communities has announced a number of additional measures
to support provision of food and assistance to vulnerable groups. Those who wish
to use the service should contact:
 the freephone COVID-19 Community Helpline number on 0808 802 0020;
 email: covid19@adviceni.net; or
 text: ACTION to 81025”.
There is also advice for vulnerable people. The need for shielding will apply to some
people who use alcohol and drugs who have one of these conditions. Alcohol and
Drug users who are also in a group that puts them at increased risk may need
additional support to follow the recommended social distancing measures.
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Commissioners, managers and staff need to consider contingency plans for
situations such as:
 reduced or interrupted supply of medicines, or access to them when
pharmacies are closed;
 reduced access to, or interrupted supply of, illicit drugs or alcohol
 resulting increased demand on services and a possible increase in crime and
aggressive behaviour;
 greater vulnerability to the effects of COVID-19 because of reduced immunity
from poor health, drug and alcohol use, or medication for other conditions;
 risk of exacerbation of breathing impairment from COVID-19 due to use of
drugs such as opioids, benzodiazepines and pregabalin;
 increased risk of domestic abuse and violence as people are forced to spend
more time in the house and are unable to obtain drugs and alcohol; and
 increased risk of harm to children whose parents or carers use drugs or
alcohol, due to increased time together if children are not at school.
Responses should include ensuring that sufficient treatment capacity is available if
people look for withdrawal support or substitute prescribing as an alternative to using
illicit drugs.
National guidance on clinical management of drug misuse and dependence and
NICE guidance on harmful drinking and alcohol dependence should be used when
considering these contingency plans.
During the COVID-19 pandemic, clinicians will have to carefully balance the potential
harms and risks of proceeding or not proceeding with prescribing an Opioid
Substitution Treatment (OST) when the level of supervised consumption has been
rapidly reduced or suspended. In most cases, it may be better to relax the regular
supervision of OSTs in a pharmacy, despite reservations about working outside of
best practice guidelines, rather than to cease prescribing this medication. Under
these circumstances measures such as those suggested by the Scottish Drug
Deaths Taskforce should be considered to help mitigate risks.
Maintaining access to OSTs and to injecting equipment must be a high priority for
drug treatment services, however OSTs should only be prescribed when the benefits
outweigh the risks.
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6. Children and Families
Changes to ways of working, such as contacting service users on the phone and by
video calling, may bring to light new information about a service user’s home life. If
staff discovers a service user is living with children, or see that a service user with
children is now struggling to cope, they should consider whether the family would
benefit from further support from their local services, community food banks and
other resources.
Children may be expected to take on inappropriate caring roles in the pandemic. A
referral to children’s social care services is then appropriate so that the child’s needs
can be properly assessed and appropriate emotional and practical support offered.
Further information on family supports is available.
Family coping mechanisms and situations can change so, in their usual contacts with
service users, practitioners should monitor potential safeguarding issues, including
the wellbeing of children, parenting and caring for vulnerable adults. Staff
supervision should include discussions about safeguarding and support from
managers or safeguarding leads. Referrals to children’s social care services or adult
safeguarding services need to be made if a child or vulnerable adult is at risk of
neglect or abuse, including parents being too sick to care for their children, or
children witnessing domestic abuse and violence.
Adfam, a national charity working to improve life for families affected by drugs and
alcohol, has produced a series of reports highlighting the serious risks, including
deaths, posed to children by opioid substitute treatments prescribed to adults. In
2018 Adfam published Opioid Substitute Treatment (OST) and risks to children:
Good Practice Guide, which again made the case for wider provision of free lockable
medication boxes to be distributed to service user who is being prescribed an OST.
Some additional key points from that report are shown below:-
Adfam (2018) Opioid Substitute Treatments (OST) and risk to children: Good
Practice Guide
 The overwhelming majority of the people who need and use OST do so
safely. However, we also must recognise that the drugs used – especially
methadone – are toxic, powerful and a clear danger to children when stored
or used in-correctly by their parents and carers, and it is for this reason that
we have developed this guide.
 Pharmacists play a key role in minimising risks to children as they are in
regular contact with drug users on OST programmes. They are therefore in
an ideal position to check that measures are being taken to reduce risk.
 When devising treatment programmes for adult drug users living with
children, those involved must take into account the risks and needs of the
children living with them.
 Safeguarding children should be a primary factor in decisions about OST,
including which drug to prescribe and whether to permit take-home doses.
 Practitioners are encouraged to work with evidence, not optimism.
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7. Mental Health
Having to stay at home and socially isolate is going to be difficult for many people
and may create mental health issues, or make existing ones worse. Many of those
attending alcohol and drug services in Northern Ireland have a key worker, they
should be advised to contact their key worker with any queries in the first instance so
their care plan can be reviewed/updated.
If service users are struggling with their mental health, they should be directed to the
Minding Your Head website. There is also an app library to support individuals. Read
the guidance for the public on the mental health and wellbeing aspects of COVID-19
for further information.
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8. Access to Opioid Substitution Treatment
In responding to restrictions on movement and its impact on services, and after
assessing and mitigating risks to patients and their households, drug treatment
services should consider the actions below in consultation with their commissioners,
Health and Social Care Trusts (HSCTs) and community pharmacies.
Community pharmacies and the medicines supply chain are under pressure as a
result of COVID-19 and there is extensive guidance for pharmacists.
Commissioners, Health and Social Care Trusts and providers should work in
collaboration with pharmacies to accommodate the needs of people who need to
access Opioid Substitution Treatment (OST), especially bearing in mind that many
pharmacies will be opening with more restricted hours, have re-organised in a way
that supervision is not feasible, and some may have to shut. Some pharmacies have
put in place cluster arrangements but these have not yet been required.
Treatment providers, pharmacies, and commissioners should be as flexible as
possible, within the legal framework, to support the safe delivery of OST.
Pharmacies will need to work closely with their local drug and alcohol services,
commissioners to support this flexible and lawful approach.
Steps to consider include:
1. OST services should continue to be delivered in line, as far as possible, with the
UK Wide Drug misuse and dependence: UK guidelines on clinical management
(2017) and the OST: NI supplementary guidance for community pharmacists.
However, given the risk imposed by COVID-19 services should use their expert
and clinical judgement to best manage the risk to all patients.
2. There will be higher and not insignificant overdose risk in some patients as a
result of these relaxations – it is essential to have ensured naloxone is offered –
even if supplied previously – and that a risk assessment which addresses risk of
overdose, safe storage, children at home, suicidal thoughts is performed and
documented for each patient.
3. As far as possible, services should now seek to assess and induct new patients
onto OST, based on a clear assessment of risk. In the absence of daily
supervision of methadone at a community pharmacy for at least the first two
weeks of the induction period, it is likely that buprenorphine will be the OST of
choice, given its better safety profile.
4. Where appropriate services should be transferring patients from supervised
consumption to take-home doses of OSTs. HSCB has agreed with Community
Pharmacy NI (CPNI) that higher risk patients identified by addiction teams will be
provided with a supervision service where possible. There may be issues with the
choice of pharmacy as not all pharmacies can provide the service due to the
challenges in respect of social distancing. Addiction services have been asked to
identify high risk patients. The HSCB Pharmacy and Medicines Management
Team is available to liaise with service providers and addiction services should
there be a necessity to find a suitable pharmacy.
13
5. HSCB has agreed with CPNI the inclusion of buprenorphine oral lyophilisate
Espranor® on the list of Substitute Prescribing medications that may be
prescribed by addiction services and dispensed via community pharmacy.
Buprenorphine oral lyophilisate Espranor® is placed on the tongue and dissolves
more quickly than other buprenorphine products which is placed under the tongue
and hence reducing the average time taken to supervise doses in a pharmacy.
Additional guidance on this product can be accessed through the BSO website
http://www.hscbusiness.hscni.net/services/3010.htm:
HSC Business Service Organisation website
Oromucosal Buprenorphine: Espranor
Espranor - Healthcare Professionals Guide
Espranor - Patient's Guide
Espranor Tear off
6. In Northern Ireland, buprenorphine prolonged-release injection (Buvidal®) is
accepted for use for the treatment of opioid dependence within a framework of
medical, social and psychological treatment. Treatment is intended for use in
adults and adolescents aged 16 years or over. Use is restricted to patients in
whom methadone is not suitable and for whom the use of buprenorphine is
considered appropriate. In Northern Ireland Buvidal® is accepted for use by
specialist addiction services only (Oct 2019)
https://niformulary.hscni.net/managed-entry/managed-entry-decisions/. HSCB has
asked Trust pharmacy services to establish supply arrangements to community
addiction services for Buvidal, taking into account its Controlled Drug status.
Buvidal® is administered by a nurse, doctor or a suitably trained pharmacist by
subcutaneous injection once weekly or once every four weeks.
NICE (2019) advised buprenorphine prolonged-release injection could be
considered as an option to other buprenorphine products in the following
circumstances. All of these factors have become even greater barriers to
maintaining patients on a conventional OST due to the restrictions on travel and
supervision imposed by the COVID-19 pandemic:-
Buprenorphine prolonged-release injection was viewed as an option by some of the
specialists for people:
 where there is a risk of diversion of opioid substitution medicines or concerns
about the safety of medicines stored at home;
 who have difficulties adhering to daily supervised opioid substitution
medication (such as if they are working or in education);
 who are stable on a therapeutic dose of sublingual buprenorphine; and
 who live in rural areas without easy access to a community pharmacy.
Source: Opioid dependence: buprenorphine prolonged release injection
(Buvidal)




During the COVID-19 pandemic, buprenorphine prolonged-release injection has
major advantages over alternative buprenorphine products or methadone,
including the following:-
 completely avoids service users needing to attend a pharmacy for
supervision or dispensing of their OST;
 completely avoids risks associated with diversion or unsafe storage as
service users never receive take home doses of this medication;
 where diversion of medication can be particularly problematic such as in
prison settings;
 reduces risk of dropping out of treatment with an OST after missing more
than 3 consecutive daily doses; and
 its long durations of action results in more gradual and less intense onset
of symptoms of acute opioid withdrawal, should service users decide to
discontinue treatment, as compared to other buprenorphine products or
methadone.
As part of their response to the COVID-19 pandemic Public Health Wales has
advised that “consideration should be given to sustainable and clinically appropriate
alternatives to existing OST supervised consumption services including the move to
provision of Buprenorphine prolonged-release injection (Buvidal)”. Scotland also
supported “a switch from current OST formulations to Buvidal injections for four
months (May-August) to all people currently on OST in prison serving sentences of
six months or longer, where it is clinically appropriate”.
https://www.gov.scot/publications/coronavirus-covid-19-opiate-substitution-
treatment-in-prisons---chief-medical-officer-letter/
Guidelines to assist clinicians who wish to prescribe buprenorphine prolonged-
release injection in both community and hospital settings are shown below:-
SMMGP (2020) Clinical guidelines for use of depot buprenorphine (Buvidal®)
in the treatment of opioid dependence
https://www.smmgp-fdap.org.uk/clinical-guidelines-for-use-of-depot-
buprenorphine-buvidal-in-the-treatment-of-opioid-dependence
Scottish Government (2020) Guidance for the use of Buvidal for Opiate





Welsh Government Coronavirus (COVID-19): Guidance for substance misuse
and homelessness services. First published: 19 March 2020
Last updated: 7 May 2020
https://gov.wales/coronavirus-covid-19-guidance-for-substance-misuse-and-
homelessness-services-htmlpublished:9 March 2020t updated:
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Given the difficulties arranging supervised consumption or even frequent
attendance of OSTs in community pharmacies the following guidance is suggested
solely based on the characteristics of the available pharmacological treatment
options:-
 Buprenorphine is preferred to methadone on safety grounds, except perhaps in
pregnancy.
 Buprenorphine prolonged-release injection (Buvidal®) would be the preferred
choice of buprenorphine as it obviates the need to attend community
pharmacies and carries none of the risks associated with diversion or unsafe
storage. Consideration should be given to other drugs of misuse and overdose
risk when contemplating use of Buvidal. Good communication needed with all
other healthcare professionals who may be prescribing other medications for
individual patients e.g. GP, A&E, OOH, prison etc. to ensure no risk of
interactions/overdose.
 Buprenorphine/naloxone combination tablets have a lower abuse potential to
other sublingual or supralingual buprenorphine monoproducts and would
therefore be preferred for services users who are receiving most of their
medication as take-home doses.
 Buprenorphine oral lyophilisate (Espranor®) is preferred to sublingual
buprenorphine monoproducts or buprenorphine/ naloxone combination tablets
when most doses are being supervised in a community pharmacy as it takes
less time to supervise before it dissolves.
Guidance on balancing the risk and benefits of increasing take home doses of opioid
substitution treatments (OSTs) during the COVID-19 pandemic.
The Scottish Drug Deaths Taskforce which was established in 2019 to tackle the
rising number of drug-related deaths in Scotland has published the following
guidance.
Information from the Scottish Drugs Deaths Taskforce regarding the challenges
presented by COVID-19 to community pharmacies and the risk of overdose for
opiate replacement therapy (ORT) patients (31 March 2020)
Context
Balancing risk of death from overdose against risk of death from COVID-19 for ORT
patients, whilst taking account of risks to all vulnerable patient groups using
pharmacies and of course pharmacy staff, is challenging. Community Pharmacies
have put in place social distancing measures to manage customer throughput and
minimise contact risk for COVID-19 for all patients, customers and staff. However
we recognise that pharmacies are under considerable additional work burden in the
current COVID-19 emergency due to increasing demand and reducing workforce.
Recommendations
We have gathered information on what plans are discussed (and in some cases
already in place) to inform this recommendation. In light of the considerable risk of
overdose for people being able to take home ORT prescriptions we urge caution in
your response. A measured and tiered response is recommended.
16
1. Changes in practice should be informed by an overdose and safety risk
assessment.
2. Those at highest risk should still receive supervised consumption.
3. Those deemed suitable can be moved to daily pick up.
4. Moves to two or three times weekly should be considered rather than moving
to weekly dispensing.
5. We do not recommend a blanket change to prescriptions at service or
prescriber level. Instead changes, if required should be made when a new
prescription is due or when a consultation takes place to ensure key
overdose prevention and safe storage advice is given.
In addition to these recommendations on ORT we recommend: Naloxone is
provided to patients on ORT and IEP.
1. There is maintained access to injecting equipment.”
2. Teams continue with non-fatal overdose post-incident management and
response.
7. Based on risk assessment, which includes an assessment of home
circumstances, children at home and arrangements for safe storage, patients may
be provided with a 1 week supply. In exceptional circumstances patients may be
provided with a two-week supply.
The Scottish Drugs Forum have suggested the following range of options to
ensure patients who are self-isolating and who are personally unable to attend
their dispensing pharmacy to collect their OST can continue to receive their
medications:-
a) A family member, trusted friend or hostel staff member acts as the
“nominated person” to collect & deliver to a patient on their behalf if no
alternative.
b) Addiction Services clinical staff member act as nominated persons
c) Use of staff working in the outreach services or other health professionals
d) Delivery to the patient by pharmacy.
e) Delivery by a wider pool of volunteers which might include medical/nursing
student’s volunteers or redeployed/previous NHS staff to act as nominated
persons. (Better if PVG cleared or police disclosure cleared)
Source: Scottish Drugs Forum – Guidance on Contingency Planning for People
who use Drugs and COVID-19 Version 2.0 Updated May 2020
8. People advised to self-isolate (but not treated in hospital) should be asked to
nominate an individual to collect the dispensed medicine on their behalf. The
nominated individual will usually need the written instruction of the patient, but
community pharmacies will receive guidance about acceptable alternatives
during the pandemic. If the patient cannot nominate someone a staff member
may, with agreed authorisation, be able to collect and deliver the medicines.
Delivery direct from pharmacy is not a commissioned community pharmacy
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service, however some community pharmacies may provide this. All these
options will be subject to local capacity and agreements.
9. Consideration might be given to implementing a system whereby a small group
of nominated individuals are authorised to collect medicines on patients’ behalf,
if it can be done safely.
10. Inform GPs of the changes in prescribing and amounts of OST stored in homes
where there are children, and inform local children’s social care services if they
are involved or if there are any concerns.
11. Work with health and justice to provide rapid access to treatment for released
prisoners and other detainees, and to understand their treatment protocols to
ensure safe continuity of care. There is a need for forward planning and good
communication to ensure safe care at the interface.
12. Work with police to provide treatment for those taken into custody.
13. Work with local services supporting isolation for people experiencing rough
sleeping to ensure continuity of care.
Mitigation of risk from the above measures should include:
 provision of take-home naloxone;
 safe storage boxes, especially if there are children in the home (but bearing
in mind that boxes have limited capacity that may not be enough for liquid
medicines if take-home doses have been increased);
 information sharing with children’s social care and other relevant
professionals (see guidance list);
 verbal and written harm reduction advice; and
 regular communication between the patient and service, enabled by the
provision of mobile phones or credit if needed.
14. Naloxone should be ordered only in quantities needed to support additional
provision, and distributed not stockpiled.
15. Best practice would be that any new dispensing measures adopted by
community pharmacies during the COVID-19 pandemic are the exception rather
than the norm and that adequate records and audit trails are maintained detailing
who received the Controlled Drugs on behalf of the patient, and that the patient
ultimately received them. The pharmacist would need to be assured that the
medicines being dispensed reach the patient. Consent etc would be required.
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9. Needle and Syringe Exchange Services
Ensuring there is an adequate supply of injecting equipment might involve:
 increasing the amount of stock held by Needle & Syringe Exchange Services
(NSES);
 allowing service users to take more equipment or providing packs with more
equipment in them;
 more outreach and peer-to-peer supply with appropriate social distancing
 allowing others to collect equipment for someone or for general peer-to-peer
distribution; and
 considering other options such as posting supplies.
Any changes in pharmacy-based NSES will need to be agreed with the pharmacies
involved.
It may also be necessary, as a last resort, to provide advice on cleaning injecting
equipment. More information on cleaning injecting equipment is in this video.
Viruses and bacteria can be spread when drugs and drinks are shared, or when
drugs are taken with unclean or shared equipment including snorting tubes and
pipes.
Information and advice are available from local drug and alcohol services and needle
and syringe programmes. FRANK and DrugandalcoholNI also have information on
how to stay safe if using drugs.
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10. Drug Detoxification
There is a significant risk of relapse which can easily lead on to an overdose which
may be fatal following withdrawal from opioids due to rapid loss of tolerance. Making
a decision to stop dependent use of opioids requires preparation, planning and a
supportive environment. Service users who are dependent on potent opioids are
more likely to achieve abstinence following an initial period of stability on an OST
and then gradually withdrawing from this medication with ongoing support.
Public Health England offers the following guidance:-
Detoxifications and dose reductions will often be deferred, with people encouraged
to maintain stability during this period of uncertainty. If necessary, services can
support community detox with resources they ring-fence for this purpose.
Source: Public Health England. COVID-19: guidance for commissioners and




For people seeking help for harmful or dependent use of benzodiazepines, the
accepted advice has been to avoid long-term prescribing of benzodiazepines. The
risk of overdose due to respiratory depression when prescribing benzodiazepines in
conjunction with opioids such as methadone was highlighted by the Medicines and
Healthcare products Regulatory Agency (MHRA) in March 2020.
Medicines and Healthcare products Regulatory Agency – Drug Safety Update (18
March 2020) Benzodiazepines and opioids: reminder of risk of potentially fatal
respiratory depression
Advice for healthcare professionals:
 benzodiazepines (and benzodiazepine-like drugs) and opioid medicines
(opioids) can both cause respiratory depression; when used together,
additive effects on the central nervous system increase the risks of sedation,
respiratory depression, coma, and death;
 only prescribe benzodiazepines (or benzodiazepine-like drugs) and opioids
together if there is no alternative;
 if a decision is made to co-prescribe, use the lowest doses possible for the
shortest duration of time and carefully monitor patients for signs of
respiratory depression;
 if there is any change in prescribing such as new interactions or dose
adjustments, re-introduce close monitoring of the patient;
 if co-prescribing methadone with a benzodiazepine or benzodiazepine-like
drug, closely monitor for respiratory depression for at least 2 weeks following
initiation or changes to prescribing because the respiratory depression effect
of methadone may be delayed; and
 advise patients of the symptoms of respiratory depression and sedation and
the need to seek immediate medical attention if these occur
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However the following guidance from the Scottish Drugs Forum suggests a
temporary maintenance dose of benzodiazepines should be considered on
pragmatic grounds for some patients during the COVID-19 pandemic.
It is important to acknowledge the absence of peer reviewed and established
evidence-based guidance on benzodiazepine prescribing. Nevertheless,
experienced prescribers working in a person centred way with clients should weigh
providing a safe supply of pharmaceutical benzodiazepines against the risk of harm
from illicit use. (page 7)
For patients at risk of benzodiazepine withdrawal, enquire which benzodiazepine
the patient is using and aim to prescribe according to current use. A tapered
protocol should be offered if an individual wishes to stop or a temporary
maintenance protocol can be considered if an individual feels they cannot stop
during self-isolation.
Daily dispensing would negate the benefits of a safe supply as it means people
cannot comply with self-isolation and it may also affect compliance with social
distancing rules. Dispensing should be in alignment with OST arrangements.
(page 8)
Source: Guidance on Contingency Planning for People who use Drugs and COVID-





11. Alcohol Harm Reduction and Detoxification
Subject to the availability of sufficient supplies, service users who are dependent on
alcohol can be given a one-month supply of thiamine on their first presentation at a
treatment service. They may be unable to obtain alcohol regularly and access to
detox support will be greatly reduced. If clinically assessed as appropriate, they
should be given advice on alcohol harm reduction, including the risks associated with
stopping drinking suddenly, and the need for stabilisation and slow reduction of daily
consumption. Staff should be competent to offer this advice.
Any reduction in alcohol services is likely to lead to greater alcohol-related morbidity
and mortality. Alcohol liaison services in acute hospitals should be continued where
this is possible and have up to date knowledge of current local alcohol services;
these can be very useful in facilitating early discharge of patients with alcohol-related
problems and so improve bed availability in acute services.
There are risks in abruptly reducing or stopping drinking in people who are severely
alcohol dependent. Those who are at particularly high risk of developing withdrawal
complications and are more likely to require emergency medical treatment if they
reduce or stop drinking abruptly include:
 service users drinking over 30 units of alcohol per day;
 those who have pre-existing epilepsy; and
 those who have a history of fits or delirium tremens during alcohol withdrawal.
These groups should be prioritised for support by specialist alcohol treatment
services during the COVID-19 pandemic and are likely to require assisted withdrawal
in an acute hospital or specialist inpatient addiction unit (note that there is likely to be
reduced capacity within inpatient units as these services are restarted), depending
on, the presence of any comorbidities or other factors.
Following clinical assessment, it will usually be appropriate to advise that this high-
risk group continue drinking for the time being, preferably at a steady level with no
large binges or days without any alcohol, to avoid severe complications of
withdrawal. They should do this until it is possible to arrange appropriate medically
supervised detoxification.
Decisions about the provision of community alcohol detoxification should be made
on a case by case basis but detoxes may have to be deferred.
Social distancing or self- and household-isolation requirements may make it
impossible to follow all the recommendations on community detox in NICE guidance
on harmful drinking and alcohol dependence. The guidance should still be referred to
for who might be suitable for community detox and for the level of support
recommended to be provided by the patient’s family.
Wherever possible, assessment should be face-to-face. For services users living
alone, community detox should only be offered in exceptional circumstances,
following an assessment of relative risks.
Based on an assessment by a competent clinician, a prescription of a recommended
benzodiazepine covering 5 to 7 days could be issued to the patient who would then
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be monitored regularly through telephone conversations or video calls. The dose of
benzodiazepine should be tailored to the level of severity of alcohol dependence as
recommended by NICE guidelines (CG115). Service users and carers should be
warned of the signs of severe alcohol withdrawal and advised to seek urgent medical
care should they occur.
An alternative approach which can be considered for those individuals who are at
low risk for serious complications during alcohol withdrawal is to gradually reduce
their alcohol consumption and avoid prescribing any benzodiazepines.
The SCOTTISH HEALTH ACTION ON ALCOHOL PROBLEMS (SHAAP) published
updated visually engaging guidance on 12 May 2020 for heavy drinkers who are
thinking about cutting back or stopping drinking alcohol during the COVID-19
pandemic which can be accessed here.
The World Health Organization has recently produced a helpful fact sheet about
the risks associated with alcohol use during the COVID-19 epidemic and which also
makes it clear that alcohol use is in no way protective against the COVID-19 virus.
Clinicians providing alcohol detox in any setting should be aware the risk of
prescribing benzodiazepines to patients with impaired respiratory function, whether
pre-existing or caused by COVID-19 infection. The risk of inducing respiratory
depression is increased when benzodiazepines are prescribed in conjunction with
opioids or other sedative drugs or in the presence of hepatic failure. .
Services should be prepared for an increase in requests for advice and support from
people who are at risk of, or experiencing, alcohol withdrawal.
Services should work closely with local services supporting isolation for people
experiencing rough sleeping to ensure continuity of care.
NHS England and NHS Improvement published the following guidance to assist
services manage and treat people with alcohol-related problems in both hospital and
community setting and where access to alcohol teams was minimal:-
Categories of people with alcohol dependence to consider
• Emergency department presentations: Consideration for the proper management
and diversion of patients presenting in alcohol withdrawal to minimise harm and reduce
representation, taking into account individual risk factors and clinical needs.
• Obligatory admissions and inpatients to acute trusts: Patients with complications
of alcohol withdrawal, for example, delirium tremens (DTs) or Wernicke Korsakoff
Syndrome (WKS), and with underlying conditions, for example, decompensated liver
disease, continue to require admission and medical management. Early identification at
triage is essential to optimise treatment and expedite discharge to minimise length of
stay and reduce likelihood of readmission.
• Obligatory admissions and inpatients to mental health trusts: Patients with
serious mental disorder and co-morbid alcohol dependence continue to require
admission and management. Early identification on admission is essential to ensure
appropriate management to avoid delay and expedite discharge to minimise length of
stay and reduce likelihood of readmission.
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• Secondary mental health community services: Patients presenting to and
managed in community mental health services with co-morbid alcohol dependence will
require more integrated management of alcohol dependence to reduce crisis
presentations.
• Primary and community care: Patients presenting to primary and community care
settings or NHS 111 should be offered harm minimisation advice and signposted to
community addiction services.
Source: NHS England and NHS Improvement. Clinical guide for the management of
people with alcohol dependence during the coronavirus pandemic 8 April 2020
Version 1
NICE guideline CG115 (February 2011) Alcohol-use disorders: diagnosis,
assessment and management of harmful drinking and alcohol dependence
SHAAP SCOTTISH HEALTH ACTION ON ALCOHOL PROBLEMS (2020)
Advice for heavy drinkers who are thinking about cutting back or stopping drinking
alcohol
https://shaap.org.uk/images/shaap-covid-pamphlet-web.pdf
NICE guideline CG115 (February 2011)
Alcohol-use disorders: diagnosis, assessment and management of harmful drinking
and alcohol dependence





Most services have already had to reduce or end face-to-face, one-to-one and group
contacts. Telephone one-to-one contacts should be maintained wherever possible.
Keeping in touch by phone generally will be important but especially for those
without internet access. Services should consider providing phones or credit to staff
and service users who don’t have them. Staff can call service users even if service
users don’t have credit to make calls.
Mutual aid groups cannot meet face-to-face while current restrictions are in place but
are providing online alternatives to meetings. It may be possible, in exceptional
circumstances, for a sponsor to visit a vulnerable, individual sponsee at home. They
should both then follow the same precautions as are required of essential services:
 stay at least 2 metres apart in an adequately ventilated area;
 both wash hands more frequently for 20 seconds;
 don’t visit if either party is showing symptoms of COVID-19 or self-isolating as
a result; and
 don’t visit those who are shielding because they are highly vulnerable or if the
sponsor themselves is from a vulnerable or extremely vulnerable group.
Sources of information, advice and support include:
 written and verbal advice on reducing harm
 telephone helplines including:
o Drinkline provides free advice and support, on 0300 123 1110;
o FRANK provides free information and advice on drugs, and information
on where to get help, on 0300 123 6600;
o the National Society for the Prevention of Cruelty to Children (NSPCC)
helpline, if there are worries about a child or young person, on 0808
800 5000;
o the National Association for Children of Alcoholics (Nacoa), on 0800
358 3456; and
o Childline provides advice for anyone under 19, on 0800 1111
 social networking apps and web chat facilities
 online help from websites including:
o https://drugsandalcoholni.info/;
o One You Drink Less, which offers advice on cutting back on alcohol;
o FRANK, which offers information and advice on drugs and where to get help;
o Down Your Drink, which provides interactive web-based support to
help people to drink more safely;
o Nacoa, which provides information, advice and support for anyone
affected by a parent’s drinking;
o Childline; and
o online access to mutual support including:
 SMART Recovery
 Alcoholics Anonymous (AA)
 Narcotics Anonymous (NA)
 Cocaine Anonymous (CA)
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13. Those not in drug and alcohol treatment
People who use drugs and alcohol and are not in drug and alcohol treatment may
also be at greater risk than others in the community from COVID-19, and even more
affected by the effects of changes in the supply of drugs and alcohol.
If it can be supported, fast access to drug and alcohol treatment for these people will
be important. It may also be necessary to consider the nature and requirements of
drug and alcohol treatment, with expectations of engagement and change reduced
so that people are more willing to attend, at least for the duration of the COVID-19
pandemic.
The supply of naloxone to those liable to use opioids, and of injecting equipment to
those who inject drugs, should be a priority.
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14. Individuals reluctant or refusing to self-isolate
There may be instances where a symptomatic individuals will not follow guidance
and advice and not self-isolate, presenting an ongoing risk of transmission to others.
In this situation it is vital to try and ascertain their concerns and, where possible, to
reassure and make appropriate arrangements to overcome these barriers.
The Health Protection (Coronavirus Restrictions) NI Regulations 2020 has agreed to
adopt powers in response to the serious and imminent threat to public health posed
by COVID-19.
Police will use the new powers to protect the health of the public and will do so using
a four-phase approach:
 engage with the public to encourage voluntary compliance;
 explain why the restrictions are vital to reduce the spread of this virus;
 encourage people to comply with the restrictions; and
 enforce where necessary when people do not listen and put others at risk. PSNI
will only do this when it is absolutely necessary.
If individuals refuse to self-isolate, staff should report this to PSNI and seek their
support and guidance.
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15. Carers and family of people who use drugs
Carers and family members must also be recognised and planned for as part of the
response. Carers UK have made these specific points:
• If carers become ill themselves with COVID-19, they may not be able to provide
care.
• If the carer lives with the person being cared for, robust plans to support the
person with care needs must be developed. It is essential that services are not
withdrawn without clear risk planning. This equally applies to a clear process for
providing emergency support for those carers who provide care with no support
from formal social care.
• Carers may not always live with the person being cared for. 76% of those
providing less than 20 hours of care per week do not live with the person they
care for.
• In the event that carers are not able to support the person needing care e.g.
travel or are looking after children unable to attend school, then it is essential
that the local health and care services have a clear picture of the person needing
support.
• Carers may have long term conditions or disabilities themselves that increase
their vulnerability, which must be factored into planning.
Services, such as Steps to Cope and Steps to Cope for those age 11-18, are
available to support carers and family members.
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16. What else commissioners and providers of drug and alcohol
treatment services can do
Providers of drug and alcohol treatment services should liaise with their local
hospitals to ensure they are aware the symptoms of COVID-19 may be confused
with withdrawal symptoms in a dependent drug or alcohol user. It is important that
anyone taken to hospital and showing symptoms that could be either alcohol or drug
withdrawal or COVID-19 is managed as if they have COVID-19 unless and until the
results of testing show otherwise.
Given the increased risks of respiratory harm in people who drink, use drugs and
smoke tobacco.
Service providers should monitor reports of contaminated, adulterated or unusually
strong drugs and unexpected effects. If usual drug supply routes are affected, there
is a risk that alternative substances will be sourced and sold. Cases should be
reported to damis@hscni.net.
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17. Cleaning and Waste
Advice on cleaning and disinfection of settings which are similar to a healthcare
setting is available. There is separate guidance for non-healthcare settings.
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18. Other sources of information
Other sector guidance and collections that service providers and commissioners
might find useful include:
 Royal College of Psychiatrists – COVID-19: Working with vulnerable people;
 European Monitoring Centre for Drugs and Drug Addiction;
 Drink and Drugs News;
 Collective Voice;
 Scottish Drugs Forum;
 Society for the Study of Addiction;
 Homeless Link; and
 Alcohol Change
Guidance for pharmacists
 Pharmaceutical Services Negotiating Committee
 Royal Pharmaceutical Society
Guidance for healthcare
 NHS guidance for people working in healthcare
 GOV.UK collection of guidance for health professionals
Guidance for particular settings
 Care homes
Guidance on children and young people
 Vulnerable children and young people
 The Children’s Commissioner
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19. Key References
Guidance on COVID-19 specific to Northern Ireland
HSC PHA COVID-19 (coronavirus): Everyone must help stop coronavirus
spreading. Accessed here.
https://www.publichealth.hscni.net/covid-19-coronavirus
HSC PHA COVID-19: What is the situation in Northern Ireland?
https://www.publichealth.hscni.net/news/covid-19-what-situation-northern-ireland
The Public Health Agency COVID-19 advice page can be found here. Previous
surveillance reports can be found here.
HSC PHA COVID-19 Health Protection
https://www.publichealth.hscni.net/directorates/public-health/health-protecti
NI Department of Health
https://www.health-ni.gov.uk/
From Sunday 19 April 2020 the Department of Health has been releasing the daily
statistics on coronavirus (COVID-19) on this site
COVID-19: GUIDANCE FOR HOMELESS PROVIDERS IN NORTHERN IRELAND




Other guidance documents and information sources from GB relating to the
COVID-19 pandemic
Information sources
As this situation is rapidly changing the most up-to-date guidance can be found on
the Public Health England website: www.gov.uk/government/collections/coronavirus-
covid-19-list-of-guidance
Advice for medical professionals can be found at:
www.gov.uk/government/collections/wuhan-novel-coronavirus
For information on guidance for healthcare professionals on COVID-19 infection in
pregnancy see: https://www.rcog.org.uk/en/guidelines-research-
services/guidelines/coronavirus-pregnancy/
Public Health England: Coronavirus (COVID-19): personal protective
equipment (PPE) plan Published 10 April 2020




Public Health England: COVID-19: guidance for stepdown of infection control
precautions within hospitals and discharging COVID-19 patients from hospital
to home settings
Published 9 April 2020




NHS England: Clinical guide for the management of people with alcohol




Welsh Government – Coronavirus (COVID-19): guidance for substance misuse and
homelessness services (version 1)
Public Health Wales: Coronavirus (COVID-19): guidance for substance misuse and
homelessness services (version 1) First published: 19 March 2020
https://phw.nhs.wales/topics/latest-information-on-novel-coronavirus-covid-
19/#Guidance7
Scottish Drugs Forum. Guidance on Contingency Planning for People who use




Scottish Government. Coronavirus (COVID-19): support for alcohol and drug
services Published 21 April 2010
https://www.gov.scot/publications/coronavirus-covid-19-support-for-alcohol-and-
drug-services/
Resources available from the Collective Voice website




 Public Health England – COVID-19: guidance for commissioners and
providers of services for people who use drugs or alcohol
 Public Health England – Guidance on residential care provision
 Public Health England – Coronavirus (COVID-19): guidance for health
professionals and other organisations
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 Public Health England/Ministry of Housing, Communities and Local
Government – COVID-19: guidance for hostel or day centre providers of
services for people experiencing rough sleeping
 Public Health England/Ministry of Justice – COVID-19: prisons and other
prescribed places of detention guidance
 Welsh Government – Coronavirus (COVID-19): guidance for substance
misuse and homelessness services (version 1)
Guidelines from Ireland on COVID-19 homelessness and addiction
Health Services Executive (HSE) and Health Protection Surveillance Centre






Drug and Alcohol Information and Support http://www.drugs.ie/resources/covid/




HSE. National Social Inclusion Office Guidance on Contingency Planning for
People who use Drugs and COVID-19 10/04/2020
https://www.hse.ie/eng/about/who/primarycare/socialinclusion/other-areas/health-
inequalities/contingency-planning-for-people-who-use-drugs.pdf
HSE National Social Inclusion Office. Guidance documents and resources
Addiction https://www.hse.ie/eng/about/who/primarycare/socialinclusion/other-
areas/health-inequalities/guidance-documents-and-resources-addiction.html
